Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...

Conagra and General Mills are among the food companies offering special options for people on GLP-1 drugs, but the products ...

Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, which in turn could put many ...

Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the fast ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.